STA
AIMT

Summit Trail Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Summit Trail Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13
Closed – – 1930
2017
Q4 		$0 Buy
+13
New +$419 ﹤0.01% 2147

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Summit Trail Advisors's AIMT Position: Q1 2018 in Review

Summit Trail Advisors sold out of Aimmune Therapeutics (AIMT) in Q1 2018, closing a stake of 13 shares.

Summit Trail Advisors first reported a position in AIMT in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 155 funds tracked by Wall St. Rank hold AIMT as of Q1 2018.

  • Summit Trail Advisors reported no remaining Aimmune Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 13 Aimmune Therapeutics shares in Q1 2018.
  • Summit Trail Advisors first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Aimmune Therapeutics position peaked at $0 in Q4 2017.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.